In Silico Analysis of Novel DPP-IV Inhibitory Peptides Released from Camel Milk Lactoferrin and the Possible Pathways Involved in Diabetes Protection

XIE Yuxia; GE Wupeng; LI Guowei; BAI Hang; ZHANG Jing; LI Xiangyun; GAO Qinyi; WANG Shuangshuang

doi:10.13386/j.issn1002-0306.2022070138

Volume 44 Issue 6

Mar. 2023

Turn off MathJax

Article Contents

Abstract

References

Science and Technology of Food Industry > 2023 > 44(6): 384-395. > DOI: 10.13386/j.issn1002-0306.2022070138

XIE Yuxia, GE Wupeng, LI Guowei, et al. In Silico Analysis of Novel DPP-IV Inhibitory Peptides Released from Camel Milk Lactoferrin and the Possible Pathways Involved in Diabetes Protection[J]. Science and Technology of Food Industry, 2023, 44(6): 384−395. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2022070138.

Citation:

PDF (4675 KB)

In Silico Analysis of Novel DPP-IV Inhibitory Peptides Released from Camel Milk Lactoferrin and the Possible Pathways Involved in Diabetes Protection

1.
College of Food Science and Engineering, Northwest A&F University, Yangling 712100, China
2.
Fuping County Inspection and Testing Center, Shaanxi Goat Milk Product Quality Supervision and Inspection Center, Weinan 711700, China
3.
XinJing Eastbart Dairy Group Co., Ltd., Xi'an 710000, China
4.
Shanxi Qinlong Dairy Industry Co., Ltd., Xi'an 710000, China

More Information

Received Date: July 13, 2022
Available Online: January 08, 2023

Graphical Abstract

Abstract

Abstract

Objective: To screen novel dipeptidyl peptidase IV (DPP-IV) inhibitory peptides from camel milk lactoferrin (LF) combined with bioinformatics. Network pharmacology was used to explore the potential mechanism of action of screened peptides on diabetes. Methods: Multiple peptides were generated by simulated enzymatic cleavage of lactoferrin using the BIOPEP website. Screening target peptides by combining peptide databases and molecular docking. Four of them were selected for solid-phase synthesis to verify their DPP-IV inhibitory activity. Molecular docking was performed to analyze the interaction between the peptide and DPP-IV molecules, and the Lineweaver-Burk method was used to analyze the inhibition mode of the peptide. Then, GPQY with stronger inhibition was selected for network pharmacological analysis to predict its potential mechanism of action on diabetes. Furthermore, the active targets of GPQY and diabetes were mined from the Swiss Target Prediction and Gene Cards databases, and the String database was used to obtain protein-protein interaction relationships. The PPI networks were built by Cytoscape 3.9.0 software, and the DAVID database was exploited for enrichment analysis of GO and KEGG signaling pathways for key targets. Results: Two DPP-IV inhibitory peptides were obtained with semi-inhibitory concentration (IC₅₀) values of 348.27±16.11 and 1024.89±19.67 μmol/L. Inhibition pattern analysis indicated competitive inhibition of GPQY and mixed-type inhibition of EACAF. Molecular docking results revealed two peptides bound to the active pocket of DPP-IV through hydrogen bonding, hydrophobic interactions and electrostatic interactions. From the PPI network analysis, GPQY had 25 core-acting targets, including STAT3, MMP9, SRC, and MAPK1. The enrichment results were based on KEGG pathways, which showed that GPQY was involved in the IL-17 signaling pathway, tumor necrosis factor (TNF) signaling pathway, renin-angiotensin system, apoptosis, etc. Conclusion: Camel milk lactoferrin is a good source of DPP-IV inhibitor peptide. GPQY could prevent diabetes and its complications through multiple targets and pathways involved in the inflammatory response and cell proliferation and differentiation.

FullText(HTML)

References (44)

References

[1]	NONGONIERMA A B, FITZGERALD R J. Prospects for the management of type 2 diabetes using food protein-derived peptides with dipeptidyl peptidase IV (DPP-IV) inhibitory activity[J]. Current Opinion in Food Science,2016,8:19−24. doi: 10.1016/j.cofs.2016.01.007
[2]	LI N, WANG L J, JIANG B, et al. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus[J]. European Journal of Medicinal Chemistry,2018,151:145−157. doi: 10.1016/j.ejmech.2018.03.041
[3]	NONGONIERMA A B, CADAMURO C, GOUIC A LE, et al. Dipeptidyl peptidase IV (DPP-IV) inhibitory properties of a camel whey protein enriched hydrolysate preparation[J]. Food Chemistry,2019,279:70−79. doi: 10.1016/j.foodchem.2018.11.142
[4]	AULIFA D L, ADNYANA I K, SUKRASNO S, et al. Inhibitory activity of xanthoangelol isolated from Ashitaba (Angelica keiskei Koidzumi) towards alpha-glucosidase and dipeptidyl peptidase-IV: In silico and in vitro studies[J]. Heliyon,2022,8(5):e09501. doi: 10.1016/j.heliyon.2022.e09501
[5]	ARNIPALLI M S, NIMMU N V, BODDAPATI S N M, et al. New enantioselective liquid chromatography method development and validation of dipeptidyl peptidase IV inhibitors using a macrocyclic glycopeptide (vancomycin) chiral stationary phase under polar ionic mode condition[J]. Chirality,2022,34(7):989−998. doi: 10.1002/chir.23448
[6]	HOWSE P M, CHIBRIKOVA L N, TWELLS L K, et al. Safety and efficacy of incretin-based therapies in patients with type 2 diabetes mellitus and CKD: A systematic review and meta-analysis[J]. Am J Kidney Dis,2016,68(5):733−742. doi: 10.1053/j.ajkd.2016.06.014
[7]	KHALESI M, SALAMI M, MOSLEHISHAD M, et al. Biomolecular content of camel milk: A traditional superfood towards future healthcare industry[J]. Trends in Food Science & Technology,2017,62:49−58.
[8]	IZADI A, KHEDMAT L, MOJTAHEDI S Y. Nutritional and therapeutic perspectives of camel milk and its protein hydrolysates: A review on versatile biofunctional properties[J]. Journal of Functional Foods,2019:60.
[9]	NONGONIERMA A B, PAOLELLA S, MUDGIL P, et al. Dipeptidyl peptidase IV (DPP-IV) inhibitory properties of camel milk protein hydrolysates generated with trypsin[J]. Journal of Functional Foods,2017,34:49−58. doi: 10.1016/j.jff.2017.04.016
[10]	MORENO-NAVARRETE J M, ORTEGA F J, RICART W, et al. Lactoferrin increases (172Thr) AMPK phosphorylation and insulin-induced (p473Ser) AKT while impairing adipocyte differentiation[J]. Journay Clin Endocrinol Metab,2009,33(9):991−1000.
[11]	MORENO-NAVARRETE J M, ORTEGA F J, BASSOLS J, et al. Decreased circulating lactoferrin in insulin resistance and altered glucose tolerance as a possible marker of neutrophil dysfunction in type 2 diabetes[J]. Journay Clin Endocrinol Metab,2009,94(10):4036−4044. doi: 10.1210/jc.2009-0215
[12]	KHAN F B, ANWAR I, REDWAN E M, et al. Camel and bovine milk lactoferrins activate insulin receptor and its related AKT and ERK1/2 pathways[J]. Journal of Dairy Science,2022,105(3):1848−1861. doi: 10.3168/jds.2021-20934
[13]	GAMAL BADR N K R, LEILA H S, BADR M, et al. Why whey? Camel whey protein as a new dietary approach to the management of free radicals and for the treatment of different health disorders[J]. Iranian Journal of Basic Medical Sciences, 2017, 20(4): 338−349.
[14]	WANG Y, HU B, FENG S, et al. Target recognition and network pharmacology for revealing anti-diabetes mechanisms of natural product[J]. Journal of Computational Science,2020:45.
[15]	侯成杰, 聂彩清, 王彦茜, 等. α-乳白蛋白源ACE抑制肽快速筛选及验证[J]. 食品科学,2021,42(24):100−107. [HOU C J, NIE C Q, WANG Y Q, et al. Rapid screening and verification of α-lactalbumin-derived ACE inhibitory peptides[J]. Food Science,2021,42(24):100−107. doi: 10.7506/spkx1002-6630-20201012-094
[16]	张颖. 牛、羊乳酪蛋白源DPP-Ⅳ抑制肽的制备、鉴定及抑制机理研究[D]. 北京: 中国农业大学, 2016 ZHANG Y. Enzymatic preparation, identification and inbition mechanism of DPP-IV inhibitory peptides derived from bovine and caprine milk casein[D]. Beijing: China Agricultural University, 2016.
[17]	ZHANG L, HAN L, MA J, et al. Exploring the synergistic and complementary effects of berberine and paeoniflorin in the treatment of type 2 diabetes mellitus by network pharmacology[J]. European Journal of Pharmacology,2022,919:174769. doi: 10.1016/j.ejphar.2022.174769
[18]	ZHAO L, ZHANG M, PAN F, et al. In silico analysis of novel dipeptidyl peptidase-IV inhibitory peptides released from Macadamia integrifolia antimicrobial protein 2 (MiAMP2) and the possible pathways involved in diabetes protection[J]. Current Research in Food Science,2021,4:603−611. doi: 10.1016/j.crfs.2021.08.008
[19]	NONGONIERMA A B, FITZGERALD R J. Features of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides from dietary proteins[J]. Journay Food Biochem,2019,43(1):e12451. doi: 10.1111/jfbc.12451
[20]	NONGONIERMA A B, FITZGERALD R J. Susceptibility of milk protein-derived peptides to dipeptidyl peptidase IV (DPP-IV) hydrolysis[J]. Food Chemistry,2014,145:845−852. doi: 10.1016/j.foodchem.2013.08.097
[21]	NONGONIERMA A B, FITZGERALD R J. An in silico model to predict the potential of dietary proteins as sources of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides[J]. Food Chemistry,2014,165:489−498. doi: 10.1016/j.foodchem.2014.05.090
[22]	WANG K, YANG X, LOU W, et al. Discovery of dipeptidyl peptidase 4 inhibitory peptides from Largemouth bass (Micropterus salmoides) by a comprehensive approach[J]. Bioorganic Chemistry,2020,105:104432. doi: 10.1016/j.bioorg.2020.104432
[23]	LACROIX I M E, LI-CHAN E C Y. Dipeptidyl peptidase-IV inhibitory activity of dairy protein hydrolysates[J]. International Dairy Journal,2012,25(2):97−102. doi: 10.1016/j.idairyj.2012.01.003
[24]	ZHAO W, ZHANG D, YU Z, et al. Novel membrane peptidase inhibitory peptides with activity against angiotensin converting enzyme and dipeptidyl peptidase IV identified from hen eggs[J]. Journal of Functional Foods,2020:64.
[25]	NONGONIERMA A B, PAOLELLA S, MUDGIL P, et al. Identification of novel dipeptidyl peptidase IV (DPP-IV) inhibitory peptides in camel milk protein hydrolysates[J]. Food Chemistry,2018,244:340−348. doi: 10.1016/j.foodchem.2017.10.033
[26]	NONGONIERMA A B, MOONEY C, SHIELDS D C, et al. In silico approaches to predict the potential of milk protein-derived peptides as dipeptidyl peptidase IV (DPP-IV) inhibitors[J]. Peptides,2014,57:43−51. doi: 10.1016/j.peptides.2014.04.018
[27]	HARNEDY-ROTHWELL P A, MCLAUGHLIN C M, O'KEEFFE M B, et al. Identification and characterisation of peptides from a boarfish (Capros aper) protein hydrolysate displaying in vitro dipeptidyl peptidase-IV (DPP-IV) inhibitory and insulinotropic activity[J]. Food Research International,2020,131:108989. doi: 10.1016/j.foodres.2020.108989
[28]	NONGONIERMA A B, FITZGERALD R J. Structure activity relationship modelling of milk protein-derived peptides with dipeptidyl peptidase IV (DPP-IV) inhibitory activity[J]. Peptides,2016,79:1−7. doi: 10.1016/j.peptides.2016.03.005
[29]	ZHANG Y, CHEN R, ZUO F, et al. Comparison of dipeptidyl peptidase IV-inhibitory activity of peptides from bovine and caprine milk casein by in silico and in vitro analyses[J]. International Dairy Journal,2016,53:37−44. doi: 10.1016/j.idairyj.2015.10.001
[30]	LACROIX I M, LI-CHAN E C. Isolation and characterization of peptides with dipeptidyl peptidase-IV inhibitory activity from pepsin-treated bovine whey proteins[J]. Peptides,2014,54:39−48. doi: 10.1016/j.peptides.2014.01.002
[31]	PAN F, ZHOU N, LI J, et al. Identification of C-phycocyanin-derived peptides as angiotensin converting enzyme and dipeptidyl peptidase IV inhibitors via molecular docking and molecular dynamic simulation[J]. ES Food & Agroforestry, 2020, 2: 58−69.
[32]	ARAKI M, KANEGAWA N, IWATA H, et al. Hydrophobic interactions at subsite S1' of human dipeptidyl peptidase IV contribute significantly to the inhibitory effect of tripeptides[J]. Heliyon,2020,6(6):e04227. doi: 10.1016/j.heliyon.2020.e04227
[33]	钱慧琴, 彭媛, 黄秀秀, 等. 基于网络药理学探讨预知子抗抑郁的作用机制[J].食品工业科技, 2021, 42 (14): 8−15 QIAN H Q, PENG Y, HUANG X X, et al. Mechanism of anti-depression mechanism of Akebiae fructus based on network pharmacology[J]. Science and Technology of Food Industry, 2021, 42(14): 8−15.
[34]	AGGARWAL B B, KUNNUMAKKARA A B, HARIKUMAR K B, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: How intimate is the relationship?[J]. New York Academy of Sciences,2009,1171:59−76. doi: 10.1111/j.1749-6632.2009.04911.x
[35]	JIANG X X, BIAN W, ZHU Y R, et al. Targeting the KCa3.1 channel suppresses diabetes-associated atherosclerosis via the STAT3/CD36 axis[J]. Diabetes Res Clin Pract,2022,185:109776. doi: 10.1016/j.diabres.2022.109776
[36]	LONG M H, ZHANG C, XU D Q, et al. PM2.5 aggravates diabetes via the systemically activated IL-6-mediated STAT3/SOCS3 pathway in rats' liver[J]. Environ Pollut,2020,256:113342. doi: 10.1016/j.envpol.2019.113342
[37]	黄锦珠, 殷贝, 毕艺鸣, 等. 柴胡-白芍药对治疗2型糖尿病的网络药理学作用机制研究[J]. 中国药业,2022,31(4):43−48. [HUANG J Z, YIN B, BI Y M, et al. Mechanism of Bupleuri radix-Paeoniae alba radix drug pairs in the treatment of type 2 diabetes mellitus based on network pharmacology[J]. China Pharmaceuticals,2022,31(4):43−48.
[38]	李芳, 曾欧, 罗健, 等. 硫化氢对糖尿病大鼠心肌纤维化及MAPK1/3和MMP-8表达的影响[J]. 南方医科大学学报,2015,35(4):549−552. [LI F, ZENG O, LUO J, et al. Effects of hydrogen sulfide on myocardial fibrosis and MAPK1/3 and MMP-8 expression in diabetic rats[J]. Journal of Southern Medical University,2015,35(4):549−552. doi: 10.3969/j.issn.1673-4254.2015.04.017
[39]	刘坤, 李娜, 程华, 等. 基于网络药理学的二陈丸治疗2型糖尿病的作用机制研究[J]. 中央民族大学学报(自然科学版),2022,31(1):78−85. [LIU K, LI N, CHEN H, et al. The effect of Er Chen Wan in the treatment of type 2 diabetes based on network pharmacology mechanism study[J]. Journal of MUC (Natural Sciences Edition),2022,31(1):78−85.
[40]	唐卫荷, 刘湘, 张玥, 等. 基于网络药理学和分子对接探讨顾步汤治疗糖尿病足作用机制的研究[J]. 中国中西医结合外科杂志,2022,28(1):106−113. [TANG W H, LIU X, ZHANG Y, et al. Study on mechanism of Gubu decoction in treatment of diabetic foot based on network pharmacology and molecular docking[J]. Chinese Journal of Surgery of Integrated Traditional and Western Medicine,2022,28(1):106−113.
[41]	RAJENDRAN S, QUESADA-MASACHS E, ZILBERMAN S, et al. IL-17 is expressed on beta and alpha cells of donors with type 1 and type 2 diabetes[J]. J Autoimmun,2021,123:102708. doi: 10.1016/j.jaut.2021.102708
[42]	AKASH M S H, REHMAN K, LIAQAT A. Tumor necrosis factor-alpha: Role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus[J]. Journay Cell Biochem,2018,119(1):105−110. doi: 10.1002/jcb.26174
[43]	LI L, EL-KHOLY W, RHODES C J, et al. Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: Role of protein kinase B[J]. Diabetologia,2005,48(7):1339−1349. doi: 10.1007/s00125-005-1787-2
[44]	LIU W, SONG D O, LAU H K, et al. Combined oral administration of GABA and DPP-4 inhibitor prevents beta cell damage and promotes beta cell regeneration in mice[J]. Front Pharmacol,2017,8:362. doi: 10.3389/fphar.2017.00362

Supplements (0)

Get Citation

PDF

XML

Article Metrics

Article views (316) PDF downloads (29)

Science and Technology of Food Industry

In Silico Analysis of Novel DPP-IV Inhibitory Peptides Released from Camel Milk Lactoferrin and the Possible Pathways Involved in Diabetes Protection

Abstract

References

Catalog

Article Metrics

Export File

Citation

Format

Content